Teach me topic of bladder cancer from symptoms till management in easy and understandable and memorizable way from cambell book of urology
bladder cancer symptoms diagnosis hematuria presentation
Selected Treatment Recommendations for Interstitial Cystitis/Bladder Pain Syndrome
Page 3
bladder cancer staging TNM classification non-muscle invasive muscle invasive
Harrison's Principles of Internal Medicine, Twenty First Edition
Page 2614
bladder cancer cystoscopy TNM staging diagram

Bailey and Love's Short Practice of Surgery 28th Edition
Page 1537
bladder cancer risk factors epidemiology transitional cell carcinoma urothelial
bladder cancer management treatment TURBT intravesical BCG chemotherapy cystectomy
Symptoms → Types → Etiology/Risk Factors → Pathology & Staging → Urology Workup (Diagnosis) → Plan (Management)
| Symptom | Clue |
|---|---|
| Frequency & Urgency | Irritative symptoms mimicking UTI |
| Dysuria | Especially in carcinoma in situ (CIS) |
| Nocturia | Bladder irritation |
| Pelvic pain | Advanced/invasive disease |
| Flank pain | Ureteral obstruction by tumor |
| Weight loss, bone pain | Metastatic disease |
💡 Memory Tip: Any adult >40 with "UTI that doesn't resolve" or "recurrent UTI in a man" → think bladder cancer!
| Type | Association |
|---|---|
| Squamous Cell Carcinoma | Chronic irritation, schistosomiasis (S. haematobium), stones |
| Adenocarcinoma | Urachal remnant, bladder exstrophy |
| Small Cell Carcinoma | Aggressive, rare, neuroendocrine origin |
| Letter | Risk Factor |
|---|---|
| S | Smoking — #1 risk factor (2–4× increased risk; 50% of all cases) |
| C | Chemical exposure (arylamines, benzidine — dye/rubber/leather workers) |
| A | Age >60 (peak incidence) |
| B | Bladder infections — chronic (Schistosoma haematobium → squamous type) |
| + | Male sex (3:1 male:female) |
| + | Aristolochic acid (herbal medicines) |
| + | Radiation (pelvic RT history) |
| + | Cyclophosphamide (chemotherapy — causes hemorrhagic cystitis → cancer) |
| + | White race more commonly affected |
Urothelium → Lamina Propria → Muscularis Propria → Perivesical Fat → Adjacent Organs

| Stage | Depth of Invasion | Category |
|---|---|---|
| Tis | Carcinoma in situ — flat, high-grade, confined to urothelium | NMIBC |
| Ta | Non-invasive papillary — confined to urothelium | NMIBC |
| T1 | Invades lamina propria (NOT muscle) | NMIBC |
| T2a | Invades inner ½ of muscularis propria | MIBC |
| T2b | Invades outer ½ of muscularis propria | MIBC |
| T3a | Microscopic perivesical fat invasion | MIBC |
| T3b | Macroscopic perivesical fat invasion | MIBC |
| T4 | Adjacent organs (prostate, vagina, rectum, pelvic wall) | MIBC |
💡 The Big Split:
- NMIBC (Non-Muscle Invasive) = Ta, T1, Tis → ~75% of cases → Treated conservatively
- MIBC (Muscle Invasive) = T2–T4 → ~18% of cases → Treated aggressively
- Metastatic = only ~3% at presentation (Harrison's, p. 2614)
| Grade | Behavior |
|---|---|
| Low Grade | Slow growing, recurs but rarely invades |
| High Grade | Aggressive, invasive potential — CIS is ALWAYS high grade |
| Test | Use |
|---|---|
| Urinalysis | Detects hematuria (micro or gross) |
| Urine Cytology | Detects shed malignant cells — HIGH specificity for high-grade/CIS; low sensitivity for low-grade |
| Urine FISH/NMP22 | Newer urine tumor markers — adjunct to cytology |
| Imaging | Purpose |
|---|---|
| CT Urography (CTU) | Upper tract evaluation (ureter, kidney — same urothelium!) |
| CT Chest/Abdomen/Pelvis | Lymph nodes, distant mets — for MIBC |
| MRI Pelvis (mpMRI) | Better soft tissue detail, staging of local invasion |
| Bone Scan | If bone pain or elevated ALP |
| PET-CT | Metastatic workup in select cases |
| Risk | Features | Treatment |
|---|---|---|
| Low Risk | Low-grade, solitary Ta, <3 cm, first occurrence | Single dose intravesical chemotherapy post-TURBT (e.g., Mitomycin C) |
| Intermediate Risk | Multifocal, recurrent, or larger low-grade | Intravesical BCG × 6 weeks (induction) OR Mitomycin C |
| High Risk | T1 high-grade, CIS, or multifocal high-grade | Intravesical BCG (induction + maintenance × 1–3 years) |
| Type | Description | Memory |
|---|---|---|
| Ileal Conduit | Ureters → loop of ileum → skin stoma (urostomy bag) | Simplest, most common |
| Orthotopic Neobladder | Ileum fashioned into pouch, connected to urethra | Patient voids normally! |
| Continent Cutaneous Reservoir | Internal pouch, catheterized via stoma | No external bag |
| Treatment | Details |
|---|---|
| 1st Line: Cisplatin-based chemo | GC (Gemcitabine + Cisplatin) or MVAC |
| If cisplatin-ineligible: | Carboplatin + Gemcitabine, or Atezolizumab/Pembrolizumab (checkpoint inhibitors) |
| 2nd Line: | Pembrolizumab (anti-PD-1), Erdafitinib (FGFR3 inhibitor if FGFR mutation), Enfortumab vedotin (ADC) |
| Maintenance: | Avelumab (checkpoint inhibitor) after platinum-based chemo |
| Stage | 5-Year Survival |
|---|---|
| NMIBC (Ta, T1) | ~80–90% |
| MIBC (T2) | ~50–60% |
| MIBC (T3–T4) | ~30–40% |
| Metastatic (M1) | <15% |
⚠️ NMIBC has a high recurrence rate (~70%) but low mortality if properly surveilled. CIS has the highest risk of progression to invasive disease.
| Feature | NMIBC | MIBC | Metastatic |
|---|---|---|---|
| Stages | Ta, T1, Tis | T2, T3, T4 | Any T, M1 |
| % at presentation | 75% | 18% | 3% |
| 1st treatment | TURBT | Neoadj chemo + Cystectomy | Platinum chemo |
| Adjuvant | Intravesical BCG/Chemo | RT ± chemo | Immunotherapy |
| Surveillance | Cystoscopy q3mo | CT imaging | Response assessment |
| 5-yr survival | 80–90% | 30–60% | <15% |